2025-05-02 22:23:15
Latest Post
Strides strengthens Anti-Inflammatory Portfolio with USFDA Approval for Celecoxib Capsules, 100 mg, 200 mg, and 400 mg
KFin Technologies Introduces New-Gen KYC Solution to Streamline Customer Onboarding
Meson Valves India Ltd receives order worth approx Rs. 12.50 crore
Oriental Rail Infrastructure Ltd receives order worth Rs. 2.46 crore
Punjab Chemicals & Crop Protection Ltd recommends dividend of Rs. 3
Stock Report
Vivo Bio Tech Ltd posts consolidated PAT of Rs. 27.71 lakhs in Q2 FY2021-22
Posted On : 2021-11-06 14:38:29( TIMEZONE : IST )
VIVO BIO TECH LTD. has reported Consolidated financial results for the period ended September 30, 2021.
Financial Results (Q2 FY2022) - QoQ Comparison
The company has reported total income of Rs. 10.1984 crores during the period ended September 30, 2021 as compared to Rs. 13.2178 crores during the period ended June 30, 2021.
The company has posted net profit / (loss) of Rs. 0.2771 crores for the period ended September 30, 2021 as against net profit / (loss) of Rs. 1.2394 crores for the period ended June 30, 2021.
The company has reported EPS of Rs. 0.19 for the period ended September 30, 2021 as compared to Rs. 0.84 for the period ended June 30, 2021.
| Financials | Q2 FY2022 | Q1 FY2022 | % Change |
| Total Income | ₹ 10.1984 crs | ₹13.2178 crs |  -22.84% |
| Net Profit | ₹0.2771 crs | ₹1.2394 crs | -77.64% |
| EPS | ₹0.19 | ₹0.84 | -77.38% |
Financial Results (Q2 FY2022) - YoY Comparison
The company has reported total income of Rs. 10.1984 crores during the period ended September 30, 2021 as compared to Rs.14.6653 crores during the period ended September 30, 2020.
The company has posted net profit / (loss) of Rs.0.2771 crores for the period ended September 30, 2021 as against net profit / (loss) of Rs.2.1043 crores for the period ended September 30, 2020.
The company has reported EPS of Rs.0.19 for the period ended September 30, 2021 as compared to Rs.1.63 for the period ended September 30, 2020.
| Financials | Q2 FY2022 | Q2 FY2021 | % Change |
| Total Income | ₹ 10.1984 crs | ₹14.6653 crs | -30.46% |
| Net Profit | ₹0.2771 crs | ₹2.1043 crs | -86.83% |
| EPS | ₹0.19 | ₹1.63 | -88.34% |
Financial Results (Half Year Ended FY2022) - YoY Comparison
The company has reported total income of Rs.23.4163 crores during the 6 Months period ended September 30, 2021 as compared to Rs.23.8193 crores during the 6 Months period ended September 30, 2020.
The company has posted net profit / (loss) of Rs.1.5165 crores for the 6 Months period ended September 30, 2021 as against net profit / (loss) of Rs.3.0819 crores for the 6 Months period ended September 30, 2020.
The company has reported EPS of Rs.1.02 for the 6 Months period ended September 30, 2021 as compared to Rs.2.39 for the 6 Months period ended September 30, 2020.
| Financials | Half Year Ended FY2022 | Half Year Ended FY2021 | % Change |
| Total Income | ₹23.4163 crs | ₹23.8193 crs | -1.69% |
| Net Profit | ₹1.5165 crs | ₹3.0819 crs | -50.79% |
| EPS | ₹1.02 | ₹2.39 | -57.32% |
Shares of VIVO BIO TECH LTD. was last trading in BSE at Rs. 72.65 as compared to the previous close of Rs. 71.30. The total number of shares traded during the day was 8498 in over 250 trades.
The stock hit an intraday high of Rs. 75.90 and intraday low of 72.00. The net turnover during the day was Rs. 622695.00.
